Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros

Base de dados
País/Região como assunto
Tipo de documento
Intervalo de ano de publicação
1.
Biomed Res Int ; 2018: 3029379, 2018.
Artigo em Inglês | MEDLINE | ID: mdl-29546054

RESUMO

OBJECTIVE: The purpose of the present study was to investigate serum trace elements in Graves' disease (GD) patients with or without orbitopathy in Northeast China. METHODS: Patients with newly diagnosed Graves' disease (HyGD) (n = 66), GD patients with euthyroid status or subclinical thyroidism after treatment (EUGD) (n = 55), GO patients with euthyroid status or subclinical thyroidism after treatment (GO) (n = 57), and normal controls (NC) (n = 66) were enrolled in this study. Serum trace elements were measured with ICP-MS. RESULTS: Serum selenium (Se) levels in EUGD group (median: 7.53 µg/dL), HyGD group (median: 6.76 µg/dL), and GO group (median: 7.40 µg/dL) were significantly lower than those in NC group (median: 9.20 µg/dL, all P < 0.01). Serum copper (Cu) levels in GO group (median: 95.93 µg/dL) were significantly lower than those in the NC group (median: 113.59 µg/dL, P = 0.015). After being adjusted for multivariables, thyroid-specific antibodies grade was associated with low Se levels. Hyperthyroidism and thyroid-specific antibodies grade were associated with high Cu levels. In addition, orbitopathy was associated with low Cu levels. CONCLUSIONS: Thyroid autoimmunity was associated with low Se levels. Hyperthyroidism and thyroid autoimmunity may be associated with relatively high serum Cu levels. Alternatively, ophthalmopathy may be related to low serum Cu levels.


Assuntos
Oftalmopatias/sangue , Doença de Graves/sangue , Hipertireoidismo/sangue , Oligoelementos/sangue , Adulto , Autoanticorpos/sangue , Autoanticorpos/imunologia , Autoimunidade/imunologia , China , Cobre/sangue , Oftalmopatias/complicações , Oftalmopatias/imunologia , Oftalmopatias/fisiopatologia , Feminino , Doença de Graves/complicações , Doença de Graves/imunologia , Doença de Graves/fisiopatologia , Humanos , Hipertireoidismo/complicações , Hipertireoidismo/imunologia , Hipertireoidismo/fisiopatologia , Masculino , Pessoa de Meia-Idade , Receptores da Tireotropina/sangue , Receptores da Tireotropina/imunologia , Selênio/sangue
2.
Ann Endocrinol (Paris) ; 72(2): 68-73, 2011 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-21511243

RESUMO

The TSH receptor expressed on the cell surface of thyroid follicular cells plays a pivotal role in the regulation of thyroid status and growth of the thyroid gland. In recent years it has become evident that the TSH receptor is also expressed widely in a variety of extrathyroidal tissues including: anterior pituitary; hypothalamus; ovary; testis; skin; kidney; immune system; bone marrow and peripheral blood cells; white and brown adipose tissue; orbital preadipocyte fibroblasts and bone. A large body of evidence is emerging to describe the functional roles of the TSH receptor at these various sites but their physiological importance in many cases remains a subject of controversy and much interest. Current understanding of the actions of the TSH receptor in extrathyroidal tissues and their possible physiological implications is discussed.


Assuntos
Receptores da Tireotropina/metabolismo , Tecido Adiposo Marrom/metabolismo , Tecido Adiposo Marrom/fisiologia , Tecido Adiposo Branco/metabolismo , Tecido Adiposo Branco/fisiologia , Animais , Osso e Ossos/metabolismo , Osso e Ossos/fisiologia , Epiderme/metabolismo , Epiderme/fisiologia , Feminino , Fibroblastos/metabolismo , Fibroblastos/fisiologia , Gônadas/metabolismo , Gônadas/fisiologia , Doença de Graves/imunologia , Doença de Graves/metabolismo , Humanos , Hipotálamo/metabolismo , Hipotálamo/fisiologia , Sistema Imunitário/metabolismo , Sistema Imunitário/fisiologia , Rim/metabolismo , Rim/fisiologia , Camundongos , Camundongos Transgênicos , Órbita/metabolismo , Adeno-Hipófise/metabolismo , Ratos , Receptores da Tireotropina/sangue , Receptores da Tireotropina/genética , Distribuição Tecidual
3.
J Clin Endocrinol Metab ; 92(8): 2984-91, 2007 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-17504907

RESUMO

CONTEXT: Central congenital hypothyroidism (CH-C) in neonates born to mothers with inadequately treated Graves' disease usually needs T(4) supplementation. The thyroid and its regulatory system have not yet been extensively studied after T(4) withdrawal, until we observed disintegrated thyroid glands in some patients. OBJECTIVE: The aim was to study the occurrence and pathogenesis of disintegrated thyroid glands in CH-C patients. DESIGN, SETTING, PATIENTS, PARTICIPANTS: Thyroid function was measured and thyroid ultrasound imaging was performed in 13 children with CH-C due to inadequately treated maternal Graves' disease after T(4)-supplementation withdrawal (group Aa). In addition, thyroid ultrasound imaging was performed in six children with CH-C born to inadequately treated mothers with Graves' disease, in whom T(4) supplementation was not withdrawn yet (group Ab) or never initiated (group Ac), in six euthyroid children born to adequately treated mothers with Graves' disease (group B), and in 10 T(4)-supplemented children with CH-C as part of multiple pituitary hormone deficiency (group C). MAIN OUTCOME MEASURES: Thyroid function and aspect (volume, echogenicity, echotexture) were measured. RESULTS: In group A, five children had developed thyroidal hypothyroidism characterized by persistently elevated TSH concentrations and exaggerated TSH responses after TRH stimulation. In the majority of patients in groups A and C, thyroid echogenicity and volume were decreased, and echotexture was inhomogeneous. Thyroid ultrasound imaging was normal in group B children. CONCLUSIONS: Inadequately treated maternal Graves' disease not only may lead to CH-C but also carries an, until now, unrecognized risk of thyroid disintegration in the offspring as well. We speculate that insufficient TSH secretion due to excessive maternal-fetal thyroid hormone transfer inhibits physiological growth and development of the child's thyroid.


Assuntos
Hipotireoidismo Congênito/etiologia , Doença de Graves/complicações , Glândula Tireoide/patologia , Glândula Tireoide/fisiologia , Adulto , Criança , Pré-Escolar , Hipotireoidismo Congênito/diagnóstico por imagem , Hipotireoidismo Congênito/patologia , Feminino , Doença de Graves/tratamento farmacológico , Doença de Graves/patologia , Humanos , Lactente , Recém-Nascido , Troca Materno-Fetal , Hormônios Hipofisários/deficiência , Gravidez , Receptores da Tireotropina/sangue , Testes de Função Tireóidea , Glândula Tireoide/diagnóstico por imagem , Tireotropina/sangue , Tiroxina/uso terapêutico , Ultrassonografia
4.
Presse Med ; 34(2 Pt 1): 94-100, 2005 Jan 29.
Artigo em Francês | MEDLINE | ID: mdl-15687976

RESUMO

INTRODUCTION: In order to evaluate the efficacy of 131 Iodine on goitre volume and on thyroid function, we studied a cohort of patients exhibiting a multinodular and toxic or non toxic goitre. METHODS: This retrospective study was conducted at the Marc Linquette clinic in Lille, in collaboration with the department of nuclear medicine. Thirty-eight patients treated with 131 Iodine were included from 1995 to 2001. Clinical examination and serum analyses including TSH, free T4 and T3, anti-thyroid peroxidase and anti-thyroglobulin antibodies and TSH-receptor antibodies measurements were conducted on inclusion and then at 3, 6, 12 and 72 months. The activity of 131 Iodine corresponded to a standard dose or was calculated according to Marinelli's method. We excluded patients who had not undergone assessment at the above-mentioned time schedules. RESULTS: The treatment was indicated in 30 patients presenting with a non compressive but toxic goitre, in 5 patients with a toxic compressive goitre and in 3 patients with a compressive but non-toxic goitre. Surgery had been excluded for all these patients because of their age, their cardiac status or because they had refused surgery after failure with prior partial thyroidectomy or medical treatment. Among the toxic goitres, TSH levels were low and T3 and T4 increased in 17 patients. In the 18 others, hyperthyroidism was manifested by an isolated decrease of TSH. The thyroid volume before treatment, assessed in 20 patients, was of 18 to 135 cm3 (mean: 53 cm3). Treatment consisted in administration of radioactivity of 3 to 30 mCi in 30 patients and standard activity of 20 to 25 mCi in 8. Functional efficacy with reduction in hyperthyroidism was noted after 3 months, and corrected in nearly all patients after 1 year, and morphological efficacy, with a mean decrease of 33.5% in the size of the goitres. No supplementary surgery was required, notably for the initially compressed goitres. Immediate and long term tolerance was satisfactory. CONCLUSION: Metabolic 131Iodine radiotherapy is effective for the functional and morphological treatment of goitres with good tolerance and few side effects. 131 Iodine is a reasonable alternative in cases with absolute or relative contraindication for surgery.


Assuntos
Bócio/tratamento farmacológico , Radioisótopos do Iodo/uso terapêutico , Idoso , Idoso de 80 Anos ou mais , Autoanticorpos/sangue , Autoanticorpos/efeitos dos fármacos , Monitoramento de Medicamentos , Uso de Medicamentos , Feminino , Bócio/sangue , Bócio/diagnóstico , Humanos , Imunoglobulinas Estimuladoras da Glândula Tireoide , Inflamação , Iodeto Peroxidase/antagonistas & inibidores , Radioisótopos do Iodo/farmacologia , Imageamento por Ressonância Magnética , Masculino , Pessoa de Meia-Idade , Tamanho do Órgão/efeitos dos fármacos , Seleção de Pacientes , Guias de Prática Clínica como Assunto , Receptores da Tireotropina/sangue , Receptores da Tireotropina/efeitos dos fármacos , Estudos Retrospectivos , Testes de Função Tireóidea , Tireotropina/sangue , Tireotropina/efeitos dos fármacos , Tiroxina/sangue , Tiroxina/efeitos dos fármacos , Resultado do Tratamento , Tri-Iodotironina/sangue , Tri-Iodotironina/efeitos dos fármacos
5.
Clin Endocrinol (Oxf) ; 47(1): 71-7, 1997 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-9302375

RESUMO

OBJECTIVE: There is little information regarding the clinical risk factors for postoperative tetany in patients with Graves' disease. We analysed the risk factors responsible for postoperative tetany by univariate and multivariate analysis in thyroidectomized patients with Graves' disease, and we discuss the mechanisms of hypocalcaemia and tetany after surgery. PATIENTS: The subjects were 1742 consecutive patients with Graves' disease who underwent subtotal thyroidectomy between 1992 and 1994. RESULTS: Univariate analysis of 15 possible risk factors demonstrated that 10 were significant: sex, required operation time, blood loss, preoperative serum calcium level, estimated weight of thyroid remnant, size of goitre, amount of excised thyroid tissue, serum alkaline phosphatase concentration, age at operation and TSH-binding inhibitory immunoglobin (TBII). In multivariate analysis in female patients, the risk factors were: preoperative lower serum calcium level, younger age, higher serum alkaline phosphatase concentration, larger size of goitre and higher value of TBII, in order of decreasing probability of significance. CONCLUSION: These results, combined with previous observations in which a significant decline in serum parathyroid hormone level was found in patients with Graves' disease who suffered postoperative tetany, suggests that postoperative tetany may occur during the period of bone restoration due to antithyroid drug therapy and be due to continuation of a calcium flux bone concomitant with transient hypoparathyroidism induced by surgery. Calcium supplements during preoperative period and/or after surgery may be appropriate for patients who are anticipated to develop postoperative tetany based on these risk factors.


Assuntos
Doença de Graves/cirurgia , Tetania/etiologia , Tireoidectomia/efeitos adversos , Adolescente , Adulto , Fatores Etários , Idoso , Fosfatase Alcalina/sangue , Autoanticorpos/sangue , Cálcio/metabolismo , Criança , Feminino , Doença de Graves/sangue , Doença de Graves/patologia , Humanos , Imunoglobulinas Estimuladoras da Glândula Tireoide , Masculino , Pessoa de Meia-Idade , Análise Multivariada , Receptores da Tireotropina/sangue , Fatores de Risco , Tetania/sangue , Tetania/patologia , Glândula Tireoide/patologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA